"Today, the U.S. Food and Drug Administration cleared the use of the XSTAT 30 wound dressing, an expandable, multi-sponge dressing used to control severe, life-threatening bleeding from wounds in areas that a tourniquet cannot be placed (such as t"...
Kinevac (Sincalide for Injection) may be used: (1) to stimulate gallbladder contraction, as may be assessed by contrast agent cholecystography or ultrasonography, or to obtain by duodenal aspiration a sample of concentrated bile for analysis of cholesterol, bile salts, phospholipids, and crystals; (2) to stimulate pancreatic secretion (especially in conjunction with secretin) prior to obtaining a duodenal aspirate for analysis of enzyme activity, composition, and cytology; (3) to accelerate the transit of a barium meal through the small bowel, thereby decreasing the time and-extent of radiation associated with fluoroscopy and x-ray examination of the intestinal tract.
DOSAGE AND ADMINISTRATION
Reconstitution and Storage
Sincalide for injection may be stored at room temperature prior to reconstitution.
To reconstitute, aseptically add 5 mL of Sterile Water for Injection USP to the vial; any additional dilution should be made with Sodium Chloride Injection USP, 0.9%. The solution may be kept at room temperature and should be used within 24 hours of reconstitution, after which time any unused portion should be discarded.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
For prompt contraction of the gallbladder, a dose of 0.02 mcg sincallde per kg (1.4 mcg/70 kg) is Injected intravenously over a 30- to 60-second interval; If satisfactory contraction of the gallbladder does not occur in 15 minutes, a second dose, 0.04 mcg sincalide per kg, may be administered. To reduce the intestinal side effects (see ADVERSE REACTIONS), an intravenous infusion may be prepared at a dose of 0.12 mcg/kg in 100 mL of Sodium Chloride Injection USP and given at a rate of 2 mL per minute; alternatively, an intramuscular dose of 0.1 mcg/kg may be given. When Kinevac (Sincalide for Injection) is used in cholecystography, roentgenograms are usually taken at five-minute Intervals after the injection. For visualization of the cystic duct, it may be necessary to take roentgenograms at one-minute intervals during the first five minutes after the injection.
For the Secretin-Kinevac (sincalide) test of pancreatic function, the patient receives a dose of 0.25 units secretin per kg by intravenous infusion over a 60-mlnute period. Thirty minutes after the initiation of the secretin infusion, a separate IV infusion of Kinevac (sincalide) at a total dose of 0.02 mcg per kg is administered over a 30-minute interval. For example, the total dose for a 70 kg patient is 1.4 mcg of sincalide; therefore, dilute 1.4 mL of reconstituted Kinevac (sincalide) solution to 30 mL with Sodium Chloride Injection USP and administer at a rate of 1 mL per minute.
To accelerate the transit time of a barium meal through the small bowel, administer Kinevac (sincalide) after the barium meal is beyond the proximal jejunum. (Sincalide, like cholecystokinin, may cause pyloric contraction.) The recommended dose is 0.04 mcg sincalide per kg (2.8 mcg/70 kg) injected intravenously over a 30- to 60-second interval; if satisfactory transit of the barium meal has not occurred in 30 minutes, a second dose of 0.04 mcg sincalide per kg may be administered. For reduction of side effects, a 30-minute IV infusion of sincalide [0.12 mcg per kg (8.4 mcg/70 kg) diluted to approximately 100 mL with Sodium Chloride Injection USP] may be administered.
Kinevac (Sincalide for Injection) is supplied in packages of 10 vials containing 5 mcg of sincalide per via] (NDC 0270-0556-15).
Store at room temperature, 15°-30° C (59°-86° F).
Manufactured for: Bracco Diagnostics Inc. Princeton, N.J. 08543. By E.R. Squibb & Sons Inc. New Brunswick, N.J. 08903. Revised November-1994. FDA Rev date: 4/26/2005This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 10/8/2008
Additional Kinevac Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.